Modi Anjali, Gamit Sukesha, Jesalpura Bharat S, Kurien George, Kosambiya Jayendra K
Department of Community Medicine, Government Medical College, Surat, Gujarat, India.
National Vector Borne Disease Control Department (NVBDCP), Health and Family Welfare Department, Government of Gujarat, Gandhinagar, Gujarat, India.
PLoS Negl Trop Dis. 2017 Apr 3;11(4):e0005476. doi: 10.1371/journal.pntd.0005476. eCollection 2017 Apr.
Following the World Health Assembly resolution on Elimination of lymphatic filariasis (ELF) as a public health problem by the year 2020, a Global Program (GPELF) was launched in 1997 to help endemic countries to initiate national programs. The current strategy to interrupt transmission of LF, is administration of once-yearly, single-dose, two-drug regimen (Albendazole with Diethylcarbamazine (DEC) to be used in endemic areas with the goal of reaching 65% epidemiological coverage for 4-6 years. We report findings of independent assessment from year 2010 to 2015 for last six rounds, after initial five rounds of Mass Drug Administration (MDA) since 2005 for ELF in endemic area of Gujarat.
Independent assessment of MDA was performed to find coverage and compliance indicators, reasons for non-coverage and non-compliance in five Implementation Units (IUs). Pre, during and post MDA evaluations were done in three phases. The impact of MDA was measured by microfilaraemia survey. A total of eight sites, four random and four fixed sentinel sites were selected to calculate microfilaria rate (MF) per IUs per year. In years 2010 to 2015, we report results from 125,936 nocturnal blood smears and 17551 population in 120 selected clusters. Four clusters were selected per year in each of the five IUs for assessment of MDA round.
Post MDA survey showed drug coverage between 81%-88% and epidemiological coverage 77%-89% across years. Main reasons for non-coverage were drug administrator related (the team did not visit or missed people) while non-compliance was population related (fear of side effects, sickness, people forgot or absent). During MDA findings show that the directly observed consumption is considerably improved from 58% in 2010 to 82% in 2015. The knowledge about benefits of drug provided also increased from 59% to 90% over the years. The current MF rate is less than one in all IUs with an overall 68% percent decrease from baseline year 2005 to year 2015. The average MF rate of Gujarat is 0.44 for year 2015.
The findings show that achieving adequate epidemiological and drug coverage is possible by actual field level operation of the program in large endemic areas. The results and feedback from independent assessment, performed regularly, could guide the policymakers and program managers for mid-term corrections and to frame strategies to enhance program. Monitoring of coverage and impact indicator together informs decisions for reaching end-point of MDA. The impact indicator- microfilaria rate in all IUs of South Gujarat Region has reached and remained less than one percent signaling end-points of MDA. Post MDA stringent monitoring in form of TAS is recommended to keep vigil on maintenance of elimination achieved.
继世界卫生大会通过到2020年消除淋巴丝虫病(ELF)这一公共卫生问题的决议后,1997年启动了全球计划(GPELF),以帮助流行国家启动国家计划。目前中断淋巴丝虫病传播的策略是每年进行一次单剂量两药疗法(阿苯达唑与乙胺嗪(DEC)联合使用),在流行地区实施,目标是在4至6年内实现65%的流行病学覆盖。我们报告了自2005年以来在古吉拉特邦流行地区进行了前五轮大规模药物给药(MDA)后,2010年至2015年最后六轮独立评估的结果。
对五个实施单位(IUs)的MDA进行独立评估,以确定覆盖和依从性指标、未覆盖和未依从的原因。在三个阶段进行MDA前、期间和后的评估。通过微丝蚴血症调查来衡量MDA的影响。总共选择了八个地点,四个随机和四个固定哨点,以计算每个IUs每年的微丝蚴率(MF)。在2010年至2015年期间,我们报告了120个选定集群中125,936份夜间血涂片和17551人的结果。在五个IUs中的每个单位每年选择四个集群进行MDA轮次的评估。
MDA后调查显示,多年来药物覆盖率在81%-88%之间,流行病学覆盖率在77%-89%之间。未覆盖的主要原因与药物管理人员有关(团队未到访或遗漏人员),而未依从与人群有关(害怕副作用、生病、人们忘记或不在)。在MDA期间的调查结果表明,直接观察到的服药率从2010年的58%大幅提高到2015年的82%。多年来,对所提供药物益处的了解也从59%增加到90%。目前所有IUs中的微丝蚴率均低于1,从2005年基线年到2015年总体下降了68%。2015年古吉拉特邦的平均微丝蚴率为0.44。
研究结果表明,通过在大型流行地区实际开展现场层面的项目运作,实现足够的流行病学和药物覆盖是可能的。定期进行的独立评估结果和反馈可为政策制定者和项目管理者提供中期纠正指导,并制定加强项目的策略。对覆盖和影响指标的监测共同为达到MDA终点的决策提供信息。南古吉拉特邦地区所有IUs的影响指标——微丝蚴率已达到并一直低于1%,标志着MDA的终点。建议在MDA后以TAS的形式进行严格监测,以密切关注所实现消除成果的维持情况。